Phibro Animal Health Corp: Form 10-Q for the period ended Dec 31, 2025
Filed with the SEC on Feb 4, 2026 and accepted by EDGAR at Feb 4, 2026, 21:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-10-01 to 2025-12-31 | $373.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2025-07-01 to 2025-12-31 | $737.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-10-01 to 2025-12-31 | $241.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-07-01 to 2025-12-31 | $485.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-10-01 to 2025-12-31 | $132.7m | us-gaap:GrossProfit |
| Gross profit | 6 months2025-07-01 to 2025-12-31 | $252.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2025-10-01 to 2025-12-31 | $82.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2025-07-01 to 2025-12-31 | $150.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-10-01 to 2025-12-31 | $50.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-07-01 to 2025-12-31 | $101.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-10-01 to 2025-12-31 | $12.5m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2025-07-01 to 2025-12-31 | $25.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-10-01 to 2025-12-31 | $9.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-07-01 to 2025-12-31 | $18.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-10-01 to 2025-12-31 | $27.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-07-01 to 2025-12-31 | $54.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-10-01 to 2025-12-31 | $0.67 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-07-01 to 2025-12-31 | $1.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-10-01 to 2025-12-31 | $0.68 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-07-01 to 2025-12-31 | $1.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-10-01 to 2025-12-31 | 40,956,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-07-01 to 2025-12-31 | 40,916,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-07-01 to 2025-12-31 | $28.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-07-01 to 2025-12-31 | $24.9m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 6 months2025-07-01 to 2025-12-31 | $9.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2025-12-31 | $55.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $862.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $1.41bn | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $282.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $1.07bn | us-gaap:Liabilities |
| Long-term debt | At period end2025-12-31 | $603.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-12-31 | $20.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-12-31 | $332.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-26-010317. Last ingested by Listed: Oct 24, 2026, 15:03 ET. Listed shows no prices and gives no investment advice.